Research Topics
| John W ParkSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted deliveryJohn W Park
Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143, USA
Clin Cancer Res 8:1172-81. 2002..We previously showed that anti-HER2 immunoliposomes bind efficiently to and internalize in HER2-overexpressing cells in vitro, resulting in intracellular drug delivery...
Liposome-based drug delivery in breast cancer treatmentJohn W Park
UCSF Comprehensive Cancer Center, San Francisco, California 94115 1710, USA
Breast Cancer Res 4:95-9. 2002....- Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancerJohn W Park
University of California, San Francisco, San Francisco, CA 94115 1710, USA
J Clin Oncol 25:3680-7. 2007..We conducted a phase I study to evaluate the safety and immunologic activity of lapuleucel-T in patients with HER-2-overexpressing metastatic breast cancer... 
Unraveling the biologic and clinical complexities of HER2John W Park
Comprehensive Cancer Center, University of California, San Francisco, CA 94115 1710, USA
Clin Breast Cancer 8:392-401. 2008..Other HER2-targeting strategies are also under active investigation...- Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug developmentJohn W Park
University of California, San Francisco Cancer Center, San Francisco, California 94115-1710, USA
Clin Cancer Res 10:3885-96. 2004 
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenograftsMichal T Krauze
Department of Neurological Surgery, University of California, San Francisco, CA 94103 0555, USA
Neuro Oncol 9:393-403. 2007..These findings have implications for further clinical applications of CED-based treatment of brain tumors...- Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brainRyuta Saito
Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, 1855 Folsom Street, Room 226, San Francisco, CA 94103, USA
Exp Neurol 196:381-9. 2005..Our ability to directly monitor and to control local delivery of liposomal drugs will most likely result in greater clinical efficacy when using CED in management of patients... - Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenograftsYoji Yamashita
Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, San Francisco, CA 94103, USA
Neuro Oncol 9:20-8. 2007..We conclude that CED of two liposomal chemotherapeutics (nLs-TPT and PLD) may be an effective treatment option for malignant gliomas... - Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced deliveryChristoph Mamot
Division of Hematology-Oncology, University of California at San Francisco, San Francisco, CA, USA
J Neurooncol 68:1-9. 2004..To our knowledge, this is the first report of CED infusion of liposomes into the CNS. We conclude that CED of liposomes in the CNS is a feasible approach, and offers a promising strategy for targeting therapeutic agents to brain tumors... - AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imagingLisa J Wilmes
Department of Radiology, University of California San Francisco, San Francisco, CA 94143 1290, USA
Magn Reson Imaging 25:319-27. 2007..Furthermore, the correlative relationship between microvasculature changes and tumor growth inhibition supports DCE-MRI methods as a biomarker of VEGF receptor target inhibition with potential clinical utility... - Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft modelRyuta Saito
Department of Neurological Surgery, University of California at San Francisco, 1855 Folsom Street, Mission Center Building Room 226, San Francisco, CA 94103, USA
Neuro Oncol 8:205-14. 2006..0005 versus control). We conclude that the combination of a novel nanoparticle Ls-TPT and CED administration was very effective in treating experimental brain tumors... - Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal modelsDmitri B Kirpotin
Hermes Biosciences Inc, South San Francisco, CA, USA
Cancer Res 66:6732-40. 2006..Immunoliposomes capable of selective internalization in cancer cells in vivo may provide new opportunities for drug delivery... - Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenograftsLaura P Serwer
Department of Neurological Surgery, University of California San Francisco, 1450 Third St, San Francisco, CA 94158, USA
Neuro Oncol 13:1288-95. 2011..These results demonstrate that intravenous delivery of nLS-TPT is a promising strategy in the treatment of GBM and support clinical investigation of this therapeutic approach... - Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cellsChristoph Mamot
Division of Hematology-Oncology, University of California, San Francisco, 94115, USA
Cancer Res 63:3154-61. 2003..We conclude that EGFR-targeted ILs provide efficient and targeted delivery of anticancer drugs in cells overexpressing EGFR or EGFRvIII... - Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosisUlrik B Nielsen
Department of Anesthesia and Pharmaceutical Chemistry, University of California-San Francisco, SF General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110, USA
Biochim Biophys Acta 1591:109-118. 2002..This strategy should be applicable to generate immunotherapeutics for other malignancies by selecting phage antibodies for internalization into other tumor types and using the scFv to target liposomes or other nanoparticles... - Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agentsMichal T Krauze
Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, California 94103, USA
J Neurosurg 103:923-9. 2005..This step-design cannula may allow reflux-free distribution and shorten the duration of infusion in future clinical applications of CED in humans... - Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigationPeter J Dickinson
Department of Surgical and Radiological Sciences, Tupper Hall, School of Veterinary Medicine, University of California, Davis, CA 95616, USA
J Neurosurg 108:989-98. 2008..Additionally any possible toxicity of liposomes containing Gd and the chemotherapeutic agent irinotecan (CPT-11) was assessed following direct intraparenchymal delivery... - The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brainPiotr Hadaczek
Laboratory of Molecular Therapeutics, Department of Neurological Surgery, UCSF, MCB, 1855 Folsom Street, Room 226, San Francisco, CA 94103, USA
Mol Ther 14:69-78. 2006.... - Future directions of liposome- and immunoliposome-based cancer therapeuticsJohn W Park
UCSF Comprehensive Cancer Center, San Francisco, CA 94115-1710, USA
Semin Oncol 31:196-205. 2004.... - Liposome-based approaches to overcome anticancer drug resistanceChristoph Mamot
Division of Hematology/Oncology, University of California, San Francisco (UCSF, 2340 Sutter Street, San Francisco, CA 94115, USA
Drug Resist Updat 6:271-9. 2003..These agents selectively deliver drug to tumor cells, can efficiently internalize for intracellular drug release, and can potentially enhance both efficacy and safety... - Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imagingRyuta Saito
Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, San Francisco, California 94103, USA
Cancer Res 64:2572-9. 2004..By permitting in vivo monitoring of therapeutic distribution in brain tumors, this technique optimizes local drug delivery and may provide a basis for clinical applications in the treatment of malignant glioma... - A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancerHope S Rugo
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, 2nd Floor, Box 1710, B 608, San Francisco, CA 94143, USA
Breast Cancer Res Treat 134:13-20. 2012..Lapatinib plus bevacizumab was active in patients with HER2-overexpressing breast cancer. The AE profile of the combination was consistent with the known profiles for these agents... - Real-time imaging and quantification of brain delivery of liposomesMichal T Krauze
Department of Neurological Surgery, Laboratory for Molecular Therapeutics, University of California San Francisco, San Francisco, California, USA
Pharm Res 23:2493-504. 2006..This review is a summary of work done by our group over the past four years... - Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imagingMichal T Krauze
Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, 1855 Folsom Street, Room 226, San Francisco, CA 94103, USA
Brain Res Brain Res Protoc 16:20-6. 2005..Findings presented in this manuscript may allow for modeling of parameters used for direct delivery of therapeutics into various regions of the brain... - Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRIKa-loh Li
Department of Radiology, University of California-San Francisco, San Francisco, California 94143-1290, USA
J Magn Reson Imaging 22:511-9. 2005..Changes in the number of voxels within certain segments of the Kps histogram were the most sensitive variable for separating control from AG-treated tumors... - Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivoKevin C Weng
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94115, USA
Nano Lett 8:2851-7. 2008..9 h as compared to free QDs with t 1/2 < 10 min. In MCF-7/HER2 xenograft models, localization of QD-ILs at tumor sites was confirmed by in vivo fluorescence imaging... - Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patientsMark Jesus M Magbanua
Division of Hematology Oncology, University of California San Francisco, San Francisco, CA 94115, USA
Cancer Res 73:30-40. 2013..Our approach may be used to explore genomic events involved in cancer progression and to monitor therapeutic efficacy of targeted therapies in clinical trials in a relatively noninvasive manner... - Biologic markers determine both the risk and the timing of recurrence in breast cancerLaura J Esserman
Department of Surgery and Radiology, University of California, San Francisco, CA 94115, USA
Breast Cancer Res Treat 129:607-16. 2011..Current signatures predict for outcome risk within 5 years of diagnosis. Predictors of late risk for HR positive disease are needed... - Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancerJorge A Garcia
Department of Medicine, University of California San Francisco, San Francisco, CA, USA
BJU Int 99:519-24. 2007.... - Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancerMark Jesus M Magbanua
Department of Medicine, Division of Hematology Oncology, University of California San Francisco, USA
BMC Cancer 12:78. 2012..However, it is the molecular characterization of CTCs that offers insight into the biology of these tumor cells in the context of personalized treatment... - Immune dysfunction and micrometastases in women with breast cancerMichael J Campbell
Department of Surgery, University of California, San Francisco, CA 94115, USA
Breast Cancer Res Treat 91:163-71. 2005..These dysregulated T cell responses did not correlate with age, stage of disease, or nodal status. However, we did observe a correlation between number of micrometastases in the bone marrow and T cell responsiveness... - Brain metastases of breast cancerMichelle E Melisko
Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
Expert Rev Anticancer Ther 5:253-68. 2005..New approaches include chemotherapy combinations, biologic therapies and novel drug-delivery strategies... - A role for biomarkers in the screening and diagnosis of breast cancer in younger womenLaura J Esserman
University of California, San Francisco, Department of Surgery, 1600 Divisadero Street, Box 1710, San Francisco, CA 94115, USA
Expert Rev Mol Diagn 7:533-44. 2007..The most effective preventive strategies will be those where a marker predicts risk for the disease, as well as the benefit from preventive interventions... - Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical resultsHope S Rugo
University of California, San Francisco Comprehensive Cancer Center, USA
J Clin Oncol 23:5474-83. 2005..The unique phase I study design allowed early identification of important absorption and metabolic issues critical to phase II testing of this agent... - Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinomaBrian I Rini
UCSF Comprehensive Cancer Center, The University of California San Francisco, 1600 Divisadero, Rm A717, San Francisco, CA 94115, USA
Cancer 101:90-5. 2004..Given the historically low objective response rate in RCC, time to disease progression (TTP) as an alternative endpoint was employed to evaluate the antitumor activity of UCN-01 in RCC... - A comparison of RNA amplification techniques at sub-nanogram input concentrationJulie E Lang
Department of Surgery, UCSF Comprehensive Cancer Center, 1500 Divisadero Street, San Francisco, CA 94143, USA
BMC Genomics 10:326. 2009..Microarray data from each amplification method were validated against quantitative real-time PCR (QPCR) for 37 genes... - Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumorMark Barok
Department of Biophysics and Cell Biology, University of Debrecen, 4012 Debrecen, Egyetem ter 1, Hungary
Cancer Lett 260:198-208. 2008..Thus, trastuzumab treatment might also be beneficial in the case of patients with breast cancer that is already trastuzumab resistant... - Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell linesMaria-Magdalena Mocanu
Department of Biophysics and Cell Biology, Research Center for Molecular Medicine, Faculty of Medicine, Medical and Health Science Center, University of Debrecen, P.O. Box 39, Nagyerdei krt. 98, H-4012 Debrecen, Hungary
Cancer Lett 227:201-12. 2005..Our results imply that the true significance of the expression profile of proteins involved in oncogenesis can only be understood after characterizing their molecular interactions... - Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategyDaryl C Drummond
Hermes Biosciences, Inc, South San Francisco, California 94080, USA
Cancer Res 66:3271-7. 2006..This study shows that intraliposomal stabilization of CPT-11 using a polymeric or highly charged, nonpolymeric polyanionic trapping agent results in a markedly active antitumor agent with low toxicity... - Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysisDavid F Nellis
SAIC-Frederick, Inc, National Cancer Institute at Frederick, PO Box B, Frederick, Maryland 21702, USA
Biotechnol Prog 21:221-32. 2005.... - Applications of fluorescence resonance energy transfer for mapping biological membranesJanos Szollosi
Department of Biophysics and Cell Biology, Faculty of Medicine, Medical and Health Science Center, University of Debrecen, Hungary
J Biotechnol 82:251-66. 2002.... - Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purificationDavid F Nellis
SAIC-Frederick, Inc, National Cancer Institute at Frederick, PO Box B, Frederick, Maryland 21702, USA
Biotechnol Prog 21:205-20. 2005..Residual endotoxin, rProtein A, and genomic DNA, were at acceptable levels. This study successfully addressed a necessary step in the scale-up of immunoliposome-encapsulated therapeutics... - Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2Peter Nagy
Department of Biophysics and Cell Biology, Medical and Health Science Center, University of Debrecen, POB 39, Debrecen H-4012, Hungary
J Cell Sci 115:4251-62. 2002..We conclude that local densities of ErbB2 and ErbB3, as well as the lipid environment profoundly influence the association properties and biological function of ErbB2... - Development of ligand-targeted liposomes for cancer therapyCharles O Noble
University of California at San Francisco, CA 94143, USA
Expert Opin Ther Targets 8:335-53. 2004..Anti-HER2 immunoliposomal doxorubicin is awaiting Phase I clinical trials, the results of which should provide new insights into the promise of ligand-targeted liposomal therapies... - Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacyCharles O Noble
Division of Hematology/Oncology, University of California at San Francisco, California 94115, USA
Cancer Res 66:2801-6. 2006..5 days; P = 0.011). We conclude that CED of nanoliposomal CPT-11 greatly prolonged tissue residence while also substantially reducing toxicity, resulting in a highly effective treatment strategy in preclinical brain tumor models... - Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I studyGlenn Liu
University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA
J Clin Oncol 23:5464-73. 2005..In addition, the day 2 vascular response measured using DCE-MRI seems to be a useful indicator of drug pharmacology, and additional research is needed to determine if it is a suitable marker for predicting clinical activity... - EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cellsChristoph Mamot
Division of Oncology, Department of Internal Medicine, University Hospital of Basel, Petersgraben 4, CH 4031 Basel, Switzerland
J Drug Target 14:215-23. 2006..We conclude that EGFR-targeted ILs derived from the humanized MAb EMD72000 provide efficient and targeted delivery of anticancer drugs in colorectal cancer cells overexpressing EGFR... - Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug deliveryRyuta Saito
Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, Mission Center Building, 94103, USA
J Neurosci Methods 154:225-32. 2006..Thus, an increased and more predictable tissue distribution can be achieved by reducing the tissue affinity of the infusate using appropriately engineered liposomes or other nanoparticles... - Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcriptionCorina Marx
Program of Cancer and Development Therapeutics, Buck Institute for Age Research, Novato, CA 94945, USA
Assay Drug Dev Technol 4:273-84. 2006.... - Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivoChristoph Mamot
Division of Hematology-Oncology, University of California at San Francisco, 94115, USA
Cancer Res 65:11631-8. 2005..001-0.003). We conclude that anti-EGFR immunoliposomes provide efficient and targeted drug delivery of anticancer compounds and may represent a useful new treatment approach for tumors that overexpress the EGFR... - Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologueGary J Kelloff
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 10:3881-4. 2004 - Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancerCorina Marx
Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd, Novato, CA 94945, USA
Mol Pharmacol 71:1525-34. 2007.... - The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancerNicholas J Robert
The Cancer Center, Inova Fairfax Hospital, Falls Church, VA, USA
Semin Oncol 31:106-46. 2004..The toxicity profile of NPLD is similar to that of conventional doxorubicin, but toxicities are less severe and NPLD is better tolerated than conventional doxorubicin at higher doses... - Selecting the right fluorophores and flow cytometer for fluorescence resonance energy transfer measurementsGabor Horvath
Department of Biophysics and Cell Biology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
Cytometry A 65:148-57. 2005..Availability of new fluorophores and cytometers requires the establishment of fluorophore dye pairs most suitable for FCET measurements... - Novel calibration method for flow cytometric fluorescence resonance energy transfer measurements between visible fluorescent proteinsPeter Nagy
Department of Biophysics and Cell Biology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
Cytometry A 67:86-96. 2005..CONCLUSIONS: We have described a straightforward novel calibration method to accurately quantitate FRET efficiency between GFP derivatives in flow cytometry...